One of the biggest obstacles to improving mortality rates for diseases such as cancer, which affects one in every two people, is late diagnoses. The Cambridge company, was spun out of chemical detection firm Owlstone in 2016 by Billy Boyle, 40. It makes a breathalyser that detects cancerous cells and can spot the disease earlier and at a lower cost than existing alternatives. Its mission is to save 100,000 patients’ lives and save health care providers $1.5bn a year. Its Breath Biopsy products are being used by GSK and AstraZeneca to identify breath-based biomarkers to support their therapeutic development programmes. It has raised a total of £56m, including £38m in a funding round in October, and investors include Horizon Ventures, Aviva Ventures and Foxconn Technologies Group.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.